Co-Diagnostics, Inc. announced that, on June 20, 2019, one of directors, Frank Kiesner, resigned as a director of the Company. Mr. Kiesner had served as a member of Board since May 24, 2017. On June 21, 2019, another of directors, Edward Borkowski, retired as a director of the Company. Mr. Borkowski had served as a member of Board since May 24, 2017. On June 25, 2019, Dr. Eugene Durenard, 53, was appointed as a director of the Company. Dr. Durenard will serve as a member of the Board's Compensation and Corporate Governance/Nominating Committee and as chair of the Audit Committee. His election underscores the Board's commitment to balance the experience and tenure of current directors with new directors who bring different perspectives, and to have the depth of experience necessary to effectively execute director succession plan. Dr. Durenard is appointed to serve as a director until his resignation or removal by the Board. On June 25, 2019, Mr. Edward L. Murphy, 56, was appointed as a director of the Company. Mr. Murphy will serve as the chair of the Board's Compensation and Corporate Governance/Nominating Committee and as a member of the Audit Committee. Mr. Murphy is appointed to serve as a director until his resignation or removal by the Board. Mr. Murphy has been senior vice president and a partner of a private investment firm from June 1999 to the present.
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
CO-DIAGNOSTICS, INC. 
